Cytokinetics CEO Robert I. Blum reports sale of $471,075 in common shares
CYTK•Cytokinetics President and CEO Robert I. Blum sold 7,500 common shares at $62.81 each on November 2, 2026, after exercising non-qualified stock options for 7,500 shares at $10.60 each.
1. Share transactions
Blum sold 7,500 common shares at $62.81 each and exercised non-qualified stock options for 7,500 common shares at $10.60 each on November 2, 2026. After the transactions, he held 278,544 common shares directly and had 134,245 non-qualified stock options remaining.
